Fresh Money for a Chlamydia Vaccine Using Synthetic Biology

09/08/2015 - 3 minutes

Prokarium Ltd today announced a new £377k (€534k) funding from SynbiCITE to develop an innovative Chlamydia vaccine using synthetic biology. The new therapy could help the 92 million people affected by Chlamydia each year and help fighting one of the most common sexually transmitted infections.

The £498k (€706k) Chlamydia vaccine project is funded at £377k (€534k) from SynbiCITE, the UK’s Innovation and Knowledge Centre for Synthetic Biology, and £121k (€172k) from Prokarium and will enable Prokarium and its collaborator Prof Robin Shattock of Imperial College to complete the pre-clinical development of the vaccine which could enter clinical trials in 2017.

With 92 million new cases worldwide per year, Chlamydia is one of the most common sexually transmitted infections in the world. Symptoms can be serious, including pelvic inflammatory disease that can lead to infertility and, in children infected by their mothers, even blindness.

Prokarium uses an innovative approach to develop its oral vaccine. The vaccine is expressed in attenuated strains of the bacteria Salmonella enterica which have been proven to be safe in clinical trials.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member